HD-OPM Archive
Topics › Plaque, CAC & CT angiography

Cyclarity's cyclodextrin approach aims to remove toxic 7-ketocholesterol from plaque

Louis Nervegna · May 25, 2026 · ♥ 3 reactions · 1 comments · original Facebook post
Plaque, CAC & CT angiographyPCSK9, ezetimibe & newer drugsInflammation & CRP
↻ This is a repost. The main version (highest ranked) is Cyclarity reports data on removing toxic 7-ketocholesterol from atherosclerotic plaque · May 23, 2026.
AI summary & key facts

Louis follows up to clarify the compound class is cyclodextrins. Cyclarity Therapeutics reported data on a small molecule designed to bind and remove 7-ketocholesterol, an oxidized cholesterol linked to inflammation and plaque instability. Early-stage company data only.

I should have explicitly mentioned that this is cyclodextrins.
See this earlier post:

facebook.com/share/r/17oRM8DUHo

Quoted:

Selective Plaque Clearance

Cyclarity Therapeutics has presented new data supporting its small molecule approach to cardiovascular disease, targeting damaged atherosclerotic plaque directly. The therapy is designed to bind and remove 7-ketocholesterol, a toxic oxidized cholesterol linked to inflammation and plaque instability in arterial walls.

Link to full video on YouTube:

▶Video · YouTube · Longevity.TechnologyLongevity.Technology UNLOCKEDLongevity.Technology UNLOCKED brings together science, business, and human potential to explore the frontier of longer, healthier living. 🎙 Mondays: In-depth...m.youtube.com

#reverseHD #7ketocholesterolHD #cyclaritytherapeuticsHD #cyclodextrinHD

Research cited

← newer: Injecting the missing AIM protein may double cat lifespan byolder: L-arginine supplements raised deaths in heart attack survivo →